News
04-22-2010, 10:25 PM
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.
More... (http://www.news-medical.net/news/20100423/Biological-activity-of-Curis-CUDC-101-HDAC-EGFR-and-HER2-inhibitor-published-in-Cancer-Research.aspx)
More... (http://www.news-medical.net/news/20100423/Biological-activity-of-Curis-CUDC-101-HDAC-EGFR-and-HER2-inhibitor-published-in-Cancer-Research.aspx)